Literature DB >> 9671117

Inhibition of myocardial L- and T-type Ca2+ currents by efonidipine: possible mechanism for its chronotropic effect.

H Masumiya1, T Shijuku, H Tanaka, K Shigenobu.   

Abstract

Effects of efonidipine, a dihydropyridine phosphonate Ca2+ channel antagonist, on the guinea-pig heart were compared with those of nifedipine. In the sino-atrial node, 1 microM efonidipine produced increase in cycle length accompanied by prolongation of the phase 4 depolarization which was not prominent with 0.1 microM nifedipine. In ventricular myocytes, both efonidipine and nifedipine produced inhibition of the L-type Ca2+ current, nifedipine being tenfold more potent than efonidipine. Efonidipine also inhibited the T-type Ca2+ current at higher concentrations but nifedipine did not. Both Ca2+ channel antagonists had no or only a weak effect on K+ currents. In addition, 40 microM Ni2+, which selectively inhibited the T-type Ca2+ current, had no effect on myocardial Ca2+ transients and contractile force. In conclusion, efonidipine was shown to have inhibitory effects on both L- and T-type Ca2+ currents, which may contribute to its high negative chronotropic potency.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671117     DOI: 10.1016/s0014-2999(98)00204-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  16 in total

Review 1.  Development of newer calcium channel antagonists: therapeutic potential of efonidipine in preventing electrical remodelling during atrial fibrillation.

Authors:  Narutaka Ohashi; Hideo Mitamura; Satoshi Ogawa
Journal:  Drugs       Date:  2009       Impact factor: 9.546

2.  A molecular signature of tissues with pacemaker activity in the heart and upper urinary tract involves coexpressed hyperpolarization-activated cation and T-type Ca2+ channels.

Authors:  Romulo Hurtado; Gil Bub; Doris Herzlinger
Journal:  FASEB J       Date:  2013-11-04       Impact factor: 5.191

3.  Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study.

Authors:  Francisco J Martinez-Martin; Alicia Macias-Batista; Cristina Comi-Diaz; Herminia Rodriguez-Rosas; Paula Soriano-Perera; Pablo Pedrianes-Martin
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

4.  Beneficial Effect of Efonidipine, an L- and T-Type Dual Calcium Channel Blocker, on Heart Rate and Blood Pressure in Patients With Mild-to-Moderate Essential Hypertension.

Authors:  Il-Young Oh; Myung-Ki Seo; Hae-Young Lee; Soon Gil Kim; Ki-Sik Kim; Won-Ho Kim; Min Soo Hyon; Kyoo-Rok Han; Se-Joong Lim; Cheol-Ho Kim
Journal:  Korean Circ J       Date:  2010-10-31       Impact factor: 3.243

5.  A selective T-type Ca2+ channel blocker R(-) efonidipine.

Authors:  Min-Chul Shin; Chang-Ju Kim; Byung-Il Min; Sachie Ogawa; Eiichiro Tanaka; Norio Akaike
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-02-16       Impact factor: 3.000

6.  New Generation Calcium Channel Blockers in Hypertensive Treatment.

Authors:  Yuri Ozawa; Koichi Hayashi; Hiroyuki Kobori
Journal:  Curr Hypertens Rev       Date:  2006-05-01

7.  Hyperpolarization-activated cation and T-type calcium ion channel expression in porcine and human renal pacemaker tissues.

Authors:  Romulo Hurtado; Carl S Smith
Journal:  J Anat       Date:  2016-01-25       Impact factor: 2.610

8.  Effects of efonidipine, an L- and T-Type dual calcium channel blocker, on heart rate and blood pressure in patients with mild to severe hypertension: an uncontrolled, open-label pilot study.

Authors:  Mitsuyuki Shimizu; Kazuhiko Ogawa; Hideki Sasaki; Yoshiki Uehara; Yumi Otsuka; Hiroyuki Okumura; Masafumi Kusaka; Toshio Hasuda; Taku Yamada; Seibu Mochizuki
Journal:  Curr Ther Res Clin Exp       Date:  2003-11

9.  Pharmacokinetics, Safety and Tolerability of Tylerdipine Hydrochloride, a Novel Dihydropyridine Dual L/T-type Calcium Channel Blocker, after Single and Multiple Oral Doses in Healthy Chinese Subjects.

Authors:  Sufeng Zhou; Yuanyuan Wang; Lu Wang; Lijun Xie; Juan Chen; Yun Liu; Hongwen Zhang; Yuqing Zhao; Ning Ou; Feng Shao
Journal:  Clin Drug Investig       Date:  2019-01       Impact factor: 2.859

10.  Identification of R(-)-isomer of efonidipine as a selective blocker of T-type Ca2+ channels.

Authors:  Taiji Furukawa; Reiko Miura; Mitsuyoshi Honda; Natsuko Kamiya; Yasuo Mori; Satoshi Takeshita; Takaaki Isshiki; Toshihide Nukada
Journal:  Br J Pharmacol       Date:  2004-11-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.